Abstract
Comparative Analysis of Harms Associated with Conservative Management and Immediate Treatment among Low Risk Localized Prostate Cancer Patients: A Population Based Study
Highlights
Prostate cancer is the second leading cause of noncutaneous cancer related deaths among men in the United States [1]
Most prostate cancers are detected by a blood test that measures Prostate Specific Antigen (PSA), and digital rectal examination [4]
Data for this study was obtained from the National Cancer Institute’s Surveillance Epidemiology Ends Results (SEER) program database linked to Medicare administrative claims from 2003 to 2009
Summary
Prostate cancer is the second leading cause of noncutaneous cancer related deaths among men in the United States [1]. Prostate cancer leads in terms of costs as well. The overall direct cost of prostate cancer in the United States in 2010 was estimated to be more than $12 billion in annual costs [3]. In 2020, the direct cost of prostate cancer is projected to be $19 billion [3]. 90% of patients receive immediate treatment for prostate cancer such as surgery or radiation therapy resulting into tremendous overtreatments [5,6].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
